X0306 4 2014-01-13 0 0000891288 QUESTCOR PHARMACEUTICALS INC QCOR 0001223697 BAILEY DON M 1300 NORTH KELLOGG DRIVE SUITE D ANAHEIM CA 92807 1 1 0 0 President and CEO Common Stock 2014-01-13 4 M 0 40000 5.10 A 139000 I Held by the Bailey 1995 Family Trust Common Stock 2014-01-13 4 S 0 21951 53.3148 D 117049 I Held by the Bailey 1995 Family Trust Common Stock 2014-01-13 4 S 0 18049 54.0351 D 99000 I Held by the Bailey 1995 Family Trust Stock Option (right to buy) 5.10 2014-01-13 4 M 0 40000 0.00 D 2019-02-25 Common Stock 40000 20000 I Held by the Bailey 1995 Family Trust As of the date of this Form 4, the reporting person holds Questcor Pharmaceuticals, Inc. stock options to purchase 1,025,000 shares of common stock; of such amount, 822,290 shares are fully vested and exercisable. The reporting person also holds 391,291 shares of Questcor Pharmaceuticals, Inc. common stock, of which 292,291 shares are held directly by the reporting person, which includes the acquisition of 974 shares of common stock through the Questcor Pharmaceuticals, Inc. Amended and Restated Employee Stock Purchase Plan. Options were granted under the Questcor Pharmaceuticals, Inc. 2006 Equity Incentive Award Plan. The option was granted on 02/26/2009 for the right to buy 220,000 shares of common stock of the Issuer. The option provided for monthly vesting over 48 months from the date of grant, with a 12-month cliff, whereby no options vested until after the twelfth month from the date of the grant. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.71-$53.70 and $53.71-$54.71, respectively. The reporting person undertakes to provide Questcor Pharmaceuticals, Inc., any security holder of Questcor Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan (the "Automatic Trading Plan") adopted by the reporting person in the second quarter of 2013 and effective 90 days post-adoption. There have been no changes to the Automatic Trading Plan since its adoption, and there have been no sales by the Reporting Person outside of the Automatic Trading Plan since its adoption. The Automatic Trading Plan controls the exact dates and amounts of sales. /s/Don M. Bailey 2014-01-15